Real-world evidence in achondroplasia: considerations for a standardized data set
-
Published:2023-06-26
Issue:1
Volume:18
Page:
-
ISSN:1750-1172
-
Container-title:Orphanet Journal of Rare Diseases
-
language:en
-
Short-container-title:Orphanet J Rare Dis
Author:
Alanay YaseminORCID, Mohnike Klaus, Nilsson Ola, Alves Inês, AlSayed Moeenaldeen, Appelman-Dijkstra Natasha M., Baujat Genevieve, Ben-Omran Tawfeg, Breyer Sandra, Cormier-Daire Valerie, Gregersen Pernille Axél, Guillén-Navarro Encarna, Högler Wolfgang, Maghnie Mohamad, Mukherjee Swati, Cohen Shelda, Pimenta Jeanne, Selicorni Angelo, Semler J. Oliver, Sigaudy Sabine, Popkov Dmitry, Sabir Ian, Noval Susana, Sessa Marco, Irving Melita
Abstract
AbstractBackgroundCollection of real-world evidence (RWE) is important in achondroplasia. Development of a prospective, shared, international resource that follows the principles of findability, accessibility, interoperability, and reuse of digital assets, and that captures long-term, high-quality data, would improve understanding of the natural history of achondroplasia, quality of life, and related outcomes.MethodsThe Europe, Middle East, and Africa (EMEA) Achondroplasia Steering Committee comprises a multidisciplinary team of 17 clinical experts and 3 advocacy organization representatives. The committee undertook an exercise to identify essential data elements for a standardized prospective registry to study the natural history of achondroplasia and related outcomes.ResultsA range of RWE on achondroplasia is being collected at EMEA centres. Whereas commonalities exist, the data elements, methods used to collect and store them, and frequency of collection vary. The topics considered most important for collection were auxological measures, sleep studies, quality of life, and neurological manifestations. Data considered essential for a prospective registry were grouped into six categories: demographics; diagnosis and patient measurements; medical issues; investigations and surgical events; medications; and outcomes possibly associated with achondroplasia treatments.ConclusionsLong-term, high-quality data are needed for this rare, multifaceted condition. Establishing registries that collect predefined data elements across age spans will provide contemporaneous prospective and longitudinal information and will be useful to improve clinical decision-making and management. It should be feasible to collect a minimum dataset with the flexibility to include country-specific criteria and pool data across countries to examine clinical outcomes associated with achondroplasia and different therapeutic approaches.
Funder
BioMarin Pharmaceutical
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference29 articles.
1. Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117–25. 2. Horton WA, Hall JG, Hecht JT. Achondroplasia. The Lancet. 2007;370:162–72. 3. Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet A. 2020;182:2297–316. 4. Hoover-Fong JE, Alade AY, Hashmi SS, Hecht JT, Legare JM, Little ME, Liu C, McGready J, Modaff P, Pauli RM, et al. Achondroplasia Natural History Study (CLARITY): a multicenter retrospective cohort study of achondroplasia in the United States. Genet Med. 2021;23:1498–505. 5. Trotter TL, Hall JG, American Academy of Pediatrics Committee on G. Health supervision for children with achondroplasia. Pediatrics. 2005;116:771–83.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|